NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $2.85 -0.13 (-4.36%) Closing price 03:59 PM EasternExtended Trading$2.86 +0.02 (+0.53%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mainz Biomed Stock (NASDAQ:MYNZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$2.75▼$3.1050-Day Range$2.93▼$6.0452-Week Range$2.65▼$40.40Volume294,274 shsAverage Volume120,883 shsMarket Capitalization$6.61 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingModerate Buy Company OverviewMainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Read More… Mainz Biomed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreMYNZ MarketRank™: Mainz Biomed scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has only been the subject of 1 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mainz Biomed's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 48.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.40% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 48.67%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.36 News SentimentMainz Biomed has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Mainz Biomed this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for MYNZ on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows5 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mainz Biomed's insider trading history. Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address MYNZ Stock News HeadlinesMainz Biomed advances in FDA approval for CRC testApril 29 at 11:20 AM | investing.comMainz Biomed Enters into Technology Partnership with EDX Medical GroupApril 29 at 8:01 AM | globenewswire.comTrump Makes Major Crypto AnnouncementTrump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick. May 2, 2025 | Crypto 101 Media (Ad)Mainz BioMed NV: Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket ApprovalApril 28, 2025 | finanznachrichten.deMainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval ProgressApril 28, 2025 | quiverquant.comMainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket ApprovalApril 28, 2025 | globenewswire.comMainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlertApril 27, 2025 | gurufocus.comMainz Biomed (MYNZ) Advances Colorectal Cancer Test With New StudyApril 27, 2025 | gurufocus.comSee More Headlines MYNZ Stock Analysis - Frequently Asked Questions How have MYNZ shares performed this year? Mainz Biomed's stock was trading at $4.32 at the start of the year. Since then, MYNZ shares have decreased by 35.2% and is now trading at $2.80. View the best growth stocks for 2025 here. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) posted its earnings results on Tuesday, August, 15th. The company reported ($22.40) EPS for the quarter, missing the consensus estimate of ($16.80) by $5.60. The company had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.25 million. When did Mainz Biomed's stock split? Mainz Biomed's stock reverse split before market open on Tuesday, December 3rd 2024. The 1-40 reverse split was announced on Friday, November 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mainz Biomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL). Company Calendar Last Earnings8/15/2023Today5/02/2025Next Earnings (Estimated)7/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MYNZ CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+381.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.19 Sales & Book Value Annual Sales$893,991.00 Price / Sales7.54 Cash FlowN/A Price / Cash FlowN/A Book Value$10.82 per share Price / Book0.27Miscellaneous Outstanding Shares2,319,000Free Float1,637,000Market Cap$6.74 million OptionableNot Optionable Beta0.53 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:MYNZ) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.